Clinical Trial Detail

NCT ID NCT03419234
Title Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Prednisone

Abiraterone + Cabazitaxel + Prednisone

Age Groups: senior adult

No variant requirements are available.